Full Press Release Details
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.
TD Cowen 46th Annual Health Care Conference
| Date / Time: | March 3, 2026, at 1:50 PM ET |
| Format: | Presentation and 1x1 investor meetings |
| Location: | Boston, MA |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, underEvents & Presentations. A replay will be available for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developedRTGel®reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visitwww.UroGen.comto learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent PerroneSenior Director, Investor Relationsvincent.perrone@urogen.com609-460-3588 ext. 1093
MEDIA:
Cindy RomanoDirector, Corporate Communicationscindy.romano@urogen.com609-460-3566 ext. 1083